{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:07:48Z","timestamp":1792782468126,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Hebrew University of Jerusalem","id":[{"id":"https:\/\/ror.org\/03qxff017","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00198-026-08109-z","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:35:56Z","timestamp":1781645756000},"page":"1667-1671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of medication-related osteonecrosis of the jaw during romosozumab treatment"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4939-5800","authenticated-orcid":false,"given":"Joshua","family":"Stokar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auryan","family":"Szalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"8109_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 80:920\u2013943","journal-title":"J Oral Maxillofac Surg"},{"key":"8109_CR2","doi-asserted-by":"publisher","first-page":"117678","DOI":"10.1016\/j.bone.2025.117678","volume":"202","author":"TY Chen","year":"2026","unstructured":"Chen TY, Deng YL, Chen IC, Lin CH, Lin JF, Chen YM, Lee HT, Hung HC (2026) Medication-related osteonecrosis of the jaw following osteoporosis therapy: a real-world retrospective cohort study using the TriNetX global collaborative network. Bone 202:117678. https:\/\/doi.org\/10.1016\/j.bone.2025.117678","journal-title":"Bone"},{"key":"8109_CR3","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.19.02192","volume":"38","author":"IW Sim","year":"2020","unstructured":"Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, PapatziamosHjelle C, Siddique M, Cook GJR, Seymour JF, Ebeling PR (2020) Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol 38:2971\u20132980","journal-title":"J Clin Oncol"},{"key":"8109_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ajoms.2025.10.015","volume":"38","author":"S Nagashio","year":"2026","unstructured":"Nagashio S, Sakai H, Kondo E, Umehara A (2026) A case of medication-related osteonecrosis of the jaw was suspected to be associated with romosozumab. J Oral Maxillofac Surg Med Pathol 38:481\u2013483. https:\/\/doi.org\/10.1016\/j.ajoms.2025.10.015","journal-title":"J Oral Maxillofac Surg Med Pathol"},{"key":"8109_CR5","doi-asserted-by":"publisher","first-page":"1017391","DOI":"10.3389\/fphar.2022.1017391","volume":"13","author":"J Peng","year":"2022","unstructured":"Peng J, Wang H, Liu Z et al (2022) Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database. Front Pharmacol 13:1017391","journal-title":"Front Pharmacol"},{"key":"8109_CR6","doi-asserted-by":"publisher","first-page":"100318","DOI":"10.1016\/j.omsc.2023.100318","volume":"9","author":"B Palla","year":"2023","unstructured":"Palla B, Anderson J, Miloro M, Moles S, Callahan N (2023) Romosozumab-associated medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Cases 9:100318","journal-title":"Oral Maxillofac Surg Cases"},{"key":"8109_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab 105:587\u2013594","journal-title":"J Clin Endocrinol Metab"},{"key":"8109_CR8","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","volume":"110","author":"J Stokar","year":"2025","unstructured":"Stokar J, Szalat A (2025) Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab 110:e861\u2013e867","journal-title":"J Clin Endocrinol Metab"},{"key":"8109_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"8109_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"8109_CR11","unstructured":"EMA (2020) Evenity : EPAR - Public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/evenity-epar-public-assessment-report_en.pdf"},{"key":"8109_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jbmr.3581","volume":"34","author":"D Hadaya","year":"2019","unstructured":"Hadaya D, Gkouveris I, Soundia A, Bezouglaia O, Boyce RW, Stolina M, Dwyer D, Dry SM, Pirih FQ, Aghaloo TL (2019) Clinically relevant doses of sclerostin antibody do not induce osteonecrosis of the jaw (ONJ) in rats with experimental periodontitis. J Bone Miner Res 34:171\u2013181","journal-title":"J Bone Miner Res"},{"key":"8109_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/odi.70331","author":"H-S Park","year":"2026","unstructured":"Park H-S, Kim S, An S-Y, Kim RH, Choi J, Kim M-Y (2026) Combined effects of romosozumab and zoledronate on the development of osteonecrosis of the jaw. Oral Dis. https:\/\/doi.org\/10.1111\/odi.70331","journal-title":"Oral Dis"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08109-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08109-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08109-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:07:44Z","timestamp":1791950864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08109-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["8109"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08109-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TriNetX provides de-identified network data; the study was given an exemption from the institutional review board and informed consent was not required.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}